Albin M, Magnani C, Krstev S, et al. Asbestos and cancer:An overview of current trends in Europe. Environ Health Perspect 1999;107 (Suppl 2):289-98.
Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89(10):716-24.
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002;41:188-201.
Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007;45:379-87.
Bovornkitti S. Asbestos and mesothelioma in Thailand.Thammasat Med J 2012;11:642-50.
Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in Norway: a populationbased study of 1,686 cases. J Thorac Oncol 2012;7:1858-61.
Offermans NS, Vermeulen R, Burdorf A, et al. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in a prospective Netherlands cohort study. J Occup Environ Med 2014;56:6-19.
Markowitz S. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. Semin Respir Crit Care Med 2015;36:334-46.
Farioli A, Ottone M, Morganti AG, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med 2016;5:950-9.
Farioli A, Violante FS, Mattioli S, et al. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database. Cancer Causes Control 2013;24(8):1535-45.
Qi F, Carbone M, Yang H, et al. Simian virus 40 transformation,malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011;5:683-97.
Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993;142:1524-33.
Carbone M, Rizzo P, Grimley PM, et al. Simian virus 40 large T antigen binds in human mesotheliomas. Nat Med 1997;3:908-12.
Sardar MR, Kuntz C, Patel T, et al. Primary pericardial mesothelioma unique case and literature review. Tex Heart Inst J 2012;39:261-4.
Nielsen LS, Baelum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer-a systematic review of the literature. Arch Environ Occup Health 2014;69:191-206.
Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17
Godar M, Liu J, Zhang P, et al. Primary pericardial mesothelioma:a rare entity. Case Rep Oncol Med 2013;2013:283601.
Suman S, Schofield P, Large S. Primary pericardial mesothelioma presenting as pericardial constriction: a case report. Heart 2004;90:e4.
Eryilmaz S, Sirlak M, Inan MB, et al. Primary pericardial mesothelioma. Cardiovasc Pathol 2001;10:147-9.
Montón CS, Esparza JFO, Ventura AB, et al. Mesothelioma of the tunica vaginalis in a patient with giant hydrocele. Radiol Bras 2016;49:63-4.
Parcesepe P, Sina S, Zanella C, et al. Case Report of a WellDifferentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature. Int JSurg Pathol 2016;24:443-7.
Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-8.
Righi L, Duregon E, Vatrano S, et al. Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study. J Thorac Oncol 2016;11(11):2006-17.
Matsuzaki H, Lee S, Kumakai-Takein N, et al. Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma. Kawasaki Med J 2015;4:13-22.
Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma:clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307-13.
Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma ofthe pleura. A phase II study. Br J Cancer 1992;65:956-60.
Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17 (Suppl 5):v7-12.
Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427-36.
Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev 2011;7:214-20.
Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition: a critical review. Anticancer Agents Med Chem 2007;7:223-45.
Hellstrom I, Friedman E, Verch T, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:1520-6.
Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics 2008;2:601-9.
